compartment

Metarrestin (ML246) is a first-in-class perinucleolar compartment inhibitor with a favorable PK profile, which effectively suppresses metastasis. Metarrestin disrupts the nucleolar structure and inhibits RNA polymerase (Pol) I transcription, at least in part by interacting with the translation elongation factor eEF1A2.

DNJNAc, also known as 2-Acetamido-1,2-dideoxynojirimycin, is a highly potent and specific inhibitor of β-hexosaminidase (HEX). HEX enzymes catalyze the hydrolysis of terminal non-reducing N-acetyl-β-D-glucosamine (GlcNAc) and N-acetyl-β-D-galactosamine (GalNAc) residues from glycoconjugates such as glycoproteins, gangliosides, and glycosaminoglycans. HEX secreted by chondrocytes into the extracellular space contributes to cartilage matrix degradation, and HEX activity is elevated in the synovial fluid of osteoarthritis patients.

SF1126 is a relevant pan and dual first-in-class PI3K BRD4 inhibitor. An RGDS-conjugated LY294002 prodrug, it is designed for increased solubility and specifically binds to integrins within the tumor compartment.

Clinodiside A in rats with one compartment open model into the body, rapid distribution, elimination rate.

Tyrosylprotein Sulfotransferase 2 (TPST-2) is a subtype of TPST. Tyrosylprotein Sulfotransferase is a fully membrane-bound glycoprotein of the trans-Golgi network with a molecular weight of 54-50 kDa. It is found in nearly all tissues studied and catalyzes the tyrosine O-sulfation of soluble and membrane proteins passing through this compartment.